Revelation Biosciences Competitors
| REVB Stock | USD 1.18 0.06 5.36% |
Correlation: Revelation Biosciences vs Biomotion Sciences Overview
Very poor diversification
Across the chosen horizon, Revelation Biosciences and Biomotion Sciences show a correlation of 0.86 and fall into the Very poor diversification bucket. This chart helps evaluate whether adding Biomotion Sciences genuinely reduces risk relative to holding Revelation Biosciences alone.
Moving together with Revelation Stock
Moving against Revelation Stock
Statistical evidence for mean reversion in Revelation Biosciences' can be observed through its tendency to revert after extreme valuations. Investors who believe in mean reversion view Revelation Biosciences' price extremes as temporary dislocations that may self-correct.
Revelation Biosciences Competition Correlation Matrix
Correlation analysis between Revelation Biosciences and its competitors provides context for understanding whether diversification is real or only superficial inside the same peer group. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Headline performance for Revelation Stock may not fully reflect how the business compares across its competitive set. Reviewing Revelation Biosciences' risk-adjusted indicators gives a clearer view of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors evaluate volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SPRC | 4.64 | -1.50 | 0.00 | -7.83 | 0.00 | 7.34 | 48.25 | |||
| ONCO | 6.85 | -1.05 | 0.00 | -0.99 | 0.00 | 11.08 | 69.59 | |||
| INDP | 5.12 | -0.26 | 0.00 | 0.03 | 0.00 | 12.00 | 51.64 | |||
| GTBP | 4.10 | -0.52 | 0.00 | -2.06 | 0.00 | 8.00 | 33.57 | |||
| SLRX | 6.68 | -1.84 | 0.00 | -1.25 | 0.00 | 16.00 | 61.05 | |||
| NKGN | 19.52 | 6.42 | 0.17 | -1.76 | 15.06 | 20.00 | 300.00 | |||
| ATXI | 10.52 | 0.45 | 0.02 | 0.08 | 13.22 | 26.09 | 122.38 | |||
| PBM | 5.59 | -1.67 | 0.00 | 5.89 | 0.00 | 9.96 | 48.52 | |||
| AZTR | 6.10 | 0.30 | 0.04 | 0.33 | 5.90 | 11.76 | 65.56 | |||
| SLXN | 4.40 | -0.46 | 0.00 | -0.21 | 0.00 | 10.98 | 32.30 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Revelation Biosciences financial statement analysis. It represents the amount of money remaining after all of Revelation Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Revelation Biosciences and related stocks such as Scisparc, Onconetix, and Indaptus Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRC | -1.7 M | -3.7 M | -3.5 M | 59.4 K | -1.9 M | -2.5 M | -2 M | -6.2 M | -8.5 M | -5.4 M | -3.5 M | -5.8 M | -2.6 M | -5.1 M | -6.3 M | -5.7 M | -5.9 M |
| ONCO | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -821.9 K | -1.6 M | -3.4 M | -13.4 M | -37.4 M | -58.7 M | -14 M | -14.7 M |
| INDP | -5.4 M | -7.6 M | -5.2 M | -5.1 M | -5.7 M | -7.2 M | -13.4 M | -28.9 M | -43.5 M | -47.6 M | -3.6 M | -7.7 M | -14.3 M | -15.4 M | -15 M | -20.8 M | -21.9 M |
| GTBP | 150 K | -3.7 M | -5.2 M | -501 K | -23.5 M | -21.5 M | 9.8 M | -144.2 M | -259.2 M | -38.6 M | -28.3 M | -58 M | -20.9 M | -7.6 M | -13.2 M | -28.4 M | -26.9 M |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | -51.2 M | 1 M | 910.6 K | 956.1 K |
| AZTR | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -8.9 M | -10.7 M | -11.3 M | -9 M | -11 M | -11.5 M |
| SLXN | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -195.9 K | -755.2 K | -3.2 M | -4.9 M | -16.4 M | -11.9 M | -11.3 M |
Revelation Biosciences Competitive Analysis
A side-by-side look at Revelation Biosciences, Scisparc, Onconetix, and Indaptus Therapeutics highlights where each stock leads or lags. Revelation Biosciences enters the comparison at 4.2 M. Revelation Biosciences posts a -131.38% return on equity, reflecting current earnings headwinds. On equity returns, Revelation Biosciences earns -131.38% compared to -1281.49% at Scisparc. Market capitalization diverges sharply here: 4.2 M versus 2.1 M, giving Revelation Biosciences a clear size advantage. Return on equity favors Revelation Biosciences at -131.38%, well ahead of Indaptus Therapeutics at -587.59%.| Better Than Average | Worse Than Peers | View Performance Chart |
Revelation Biosciences Competition Peer Performance Charts
How to Analyze Revelation Biosciences Against Peers
Revelation Biosciences' peer analysis compares Revelation Biosciences with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Revelation Biosciences trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Revelation Biosciences leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Revelation Biosciences' return on invested capital tops the peer average, meaning each dollar of capital is working harder here. Peer rankings that stay stable over multiple quarters tend to reflect structural edges rather than short-term luck. Peer analysis may also reveal when current market leaders are beginning to converge back toward group averages. For peer comparison, Revelation Biosciences has a market cap of 4.17 M, P/E of 8.69.
The analytics block for Revelation Biosciences relies on periodic company reporting and market reference feeds, with quality checks and normalization applied before rendering. Timing can vary by data vendor.